ClinicalTrials.gg
CompletedNCT05816057Updated Jan 3, 2024

A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

A Phase 3 interventional study of semaglutide injection in Diabetes Mellitus, Type 2, sponsored by Hangzhou Jiuyuan Gene Engineering Co. Ltd.,. Completed at 35 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-03.

Sponsored by Hangzhou Jiuyuan Gene Engineering Co. Ltd., · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2022, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
476
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
43rd of 163
476 · median 104
Started
2022
with 17 others
Phase 3
57 of 163
7 open now
Registered
112th of 163
by date

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 43rd largest by enrollment, is one of 18 that started in 2022, is one of 57 in phase 3, and was the 112th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Semaglutide injection is a new drug developed according to Ozempic® biosimilars.This trial is conducted in China. The purpose of this study is to investigate the similarities in the efficacy and safety of semaglutide injection and Ozempic® in the treatment of type 2 diabetes, respectively.

Read the detailed description

This study is a multicenter, randomized, open-label, parallel assignment, which plans to enroll 476 patients with type 2 diabetes And Stable daily dose for 4 weeks prior to the day of screening of the metformin formulations (greater than or equal to 1500 mg to less than or equal to 2000 mg or maximum tolerated dose documented greater than or equal to 1000 mg. The study was divided into three phases: screening, baseline and treatment.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate in the trial and sign the form;
  2. Diagnosed with type 2 diabetes And Stable daily dose for 4 weeks prior to the day of screening of the metformin formulations (greater than or equal to 1500 mg to less than or equal to 2000 mg or maximum tolerated dose documented greater than or equal to 1000 mg);
  3. Male or female, Aged 18-75 years (both inclusive) at the time of signing informed consent;
  4. (HbA1c) of greater than 7.0% to less than or less than or equal to 11.0%.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any medication for the indication of diabetes other than stated in the inclusion criteria within the past 4 weeks prior to the day of screening. However, short-term insulin treatment for a maximum of 7 days prior to the day of screening is allowed;
  2. Systemic (excluding topical and inhaled preparations) within the past 90 days to the day of screening;
  3. Known or suspected to trial product(s) or related products;
  4. Have participated in other clinical trials and used drugs within the past 90 days to the day of screening;
  5. Heart failure(Subjects presently classified as being in Class IV); Acute coronary syndrome or cerebrovascular events, including but not limited to acute myocardial infarction, stroke, unstable angina or ; Have undergone heart-related surgery; or investigator assessment of severe abnormalities, poorly controlled hypertension (defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg), and other cardiovascular and cerebrovascular disorders that are not suitable within the past 90 days prior to the day of screening;
  6. Known to plan to be hospitalized for any surgery at the time of screening;
  7. Hyperthyroidism, Cushing's syndrome, Diabetic gastroparesis or other gastrointestinal disorders; Gastrointestinal disorders assessed by investigators as increasing post-medication risk, anorexia, alcohol dependence, drug use, drug dependence, epilepsy, psychiatric illness, need for systemic anti-infective therapy, or other conditions assessed by investigators as affecting endpoint assessment;
  8. Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary Thyroid Carcinoma (MTC);
  9. History or presence of pancreatitis (acute or chronic);
  10. Proliferative diabetic retinopathy.
  11. Recurrent severe hypoglycaemia (more than 3 severe hypoglycaemic events) within the past 90 days to the day of screening;
  12. Acute metabolic complications within the past 180 days prior to the day of screening;
  13. Subjects with calcitonin ≥ 50 ng/L pg/mL) ,AMY ≥3×upper normal limit (UNL), triglyceride ≥5.7 mmol/L( 500 mg/dL) ,\<60 mL/min/1.73 m2,; ≤120 g/L (male) or ≤110 g/L (female), 、AST≥ 2.5 ×UNL,≥2×;
  14. History or presence of malignant neoplasms within the last 5 years (except basal or squamous cell skin cancer and carcinoma in situ);
  15. The female who is pregnant, breast-feeding or Female/male intends to become pregnant or is of and not using highly effective method; (16))Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
476 participants (actual)

Study arms

  • Experimental
    semaglutide injection

    Semaglutide 0.25 mg、0.5 mg、1.0mg

    Biological: semaglutide injection

  • Active comparator
    ozempic®

    Ozempic® 0.25 mg、0.5 mg、1.0mg

    Biological: semaglutide injection

Interventions

  • The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.

06

What researchers measure

Primary outcomes

  1. The observed mean change in Glycosylated Haemoglobin A1c (HbA1c) values from baseline after 32 weeks of treatment.

    Time frame: 32 weeks

Secondary outcomes

  1. The observed mean change in HbA1c values from baseline after 20 weeks of treatment.

    Time frame: 20 weeks

  2. Change From Baseline to Week 20 in Fasting Plasma Glucose (FPG).

    Time frame: 20 weeks

  3. Change From Baseline to Week 32 in Fasting Plasma Glucose (FPG).

    Time frame: 32 weeks

  4. Change From Baseline to Week 32 in HbA1c < 7.0% of participants.

    Time frame: 32 weeks

  5. Change From Baseline to Week 32 in HbA1c≤6.5% of participants.

    Time frame: 32 weeks

  6. Change From Baseline to Week 32 in HbA1c < 7.0% of participants with no hypoglycemic events.

    Time frame: 32 weeks

  7. Change From Baseline to Week 32 in Body Weight (Kilogram (kg)).

    Time frame: 32 weeks

  8. Change From Baseline to Week 32 in Systolic and Diastolic Blood Pressure.

    Time frame: 32 weeks

  9. Change From Baseline to Week 32 in Pulse Rate.

    Time frame: 32 weeks

  10. Change From Baseline to Week 32 in Fasting Blood Lipids: Total Cholesterol、Low-density Lipoprotein (LDL) Cholesterol、 High-density Lipoprotein (HDL) Cholesterol 、Triglycerides (Ratio to Baseline).

    Time frame: 32weeks

07

Study locations

35 sites
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • NanFang Hospital
    Guangzhou, Guangdong 510000, China
  • CANGZHOU People's Hospital
    Cangzhou, Hebei 61000, China
  • CANGZHOU Central Hospital
    Cangzhou, Hebei 61001, China
  • Cang zhou Hospital of Integrated Traditional Chinese and Western of Hebei Province
    Cangzhou, Hebei 61013, China
  • Shijiazhuang Second Hospital
    Shijiazhuang, Hebei 050000, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 450052, China
  • Nanyang First People's Hospital
    Nanyang, Henan 473000, China
  • Nanyang Second General Hospital
    Nanyang, Henan 473000, China
  • The First Affiliated Hospital of Nanyang Medical College
    Nanyang, Henan 473000, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450014, China
  • Huangshi Central Hospital
    Huangshi, Hubei 435000, China
  • Yichang Central People's Hospital
    Yichang, Hubei 443003, China
  • Huizhou Central People's Hospital
    Guangdong, Huizhou 516003, China
  • Yueyang People's Hospital
    Yueyang, Hunan 414000, China
  • BaogangHospital of InnerMongolia
    Baotou, Inner Mongolia 014000, China
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 010000, China
  • Changzhou No.2 People's Hospital
    Changzhou, Jiangsu 213003, China
  • Huai'an Second People's Hospital
    Huaian, Jiangsu 223000, China
  • The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University
    Huaian, Jiangsu 223000, China
  • The Second People's Hospital of Lianyungang
    Lianyungang, Jiangsu 222006, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • The First Affiliated Hospital OF Soochow University
    Suzhou, Jiangsu 215006, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
  • Xuzhou Cancer Hospital
    Xuzhou, Jiangsu 221000, China
  • Affiliated Hospital of Jiangsu University
    Zhengjiang, Jiangsu 212001, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi 0799-6881723, China
  • The First Affiliated Hospital of Xi'an jiaotong university
    Xi'an, Shaanxi 710000, China
  • Central Hospital Affiliated to Shandong First Medical University
    Jinan, Shandong 250000, China
  • Huadong Hospital Affillated to Fudan University
    Shanghai, Shanghai 200030, China
  • Zhongshan Hospital
    Shanghai, Shanghai 200030, China
  • Shanghai Pudong New Area People's Hospital
    Shanghai, Shanghai 201299, China
  • Jincheng Grand Hospital
    Jincheng, Shanxi 048006, China
  • Shanxi Yuncheng Central Hospital
    Yuncheng, Shanxi 044099, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jul 2023, 12 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 12 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2023
First posted
Apr 18, 2023
StartActual
Jul 25, 2022
Primary completionActual
Jul 25, 2023
CompletionActual
Oct 31, 2023
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05816057
Lead sponsor
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Jul 25, 2022
Primary completion
Jul 25, 2023
Completion
Oct 31, 2023
Last update
Jan 3, 2024

Study contacts

xiaoying Li, M.D.
principal investigator · Shanghai Zhongshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion